RPG Life Sciences Launches Naprosyn ES in India; Firm Reports 14% Net Profit Growth
RPG Life Sciences enters an exclusive marketing agreement with Archerchem to launch Naprosyn ES, a value-added pharmaceutical combination targeting the Indian pain relief market. This follows a…
Read the full articleYou might also wanna read
RPG Life Sciences launches Naprosyn ES, a first-in-India Naproxen-Esomeprazole combination
The product targets patients on long-term NSAID therapy who face elevated risk of gastrointestinal complications.
Indian Pharma Q1FY27: Revenue up, but profits to dip, says report
Indian pharma firms are set for improved Q1FY27 revenues, but a Goldman Sachs report warns of declining margins. This is due to an unfavorab
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock
Louis Navellier's strategy identifies high-potential stocks with eight fundamental rules, and Alnylam Pharmaceuticals (ALNY) perfectly fits
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will repo
India-Origin Pharma Patents Jump Four-Fold, Innovation Pipeline Tops 1,095: Report
India’s pharmaceutical sector sees rapid growth in patents and drug discovery programmes, marking a shift toward innovation.
India’s lifesciences sector sees momentum build in innovation: BCG -HealthKois report
Private equity and venture capital investment in pharma rose 2.1x in five years to $ 731 million for the year ended March 2026, and biotech
Comments
Sign in to join the conversation.
No comments yet. Be the first.